Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-hodgkin's lymphoma xenografts

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Secchiero, Paola ^a   Zorzet, Sonia ^b   Tripodo, Claudio ^c   Corallini, Federica ^a   Melloni, Elisabetta ^a   Caruso, Lorenzo ^a   Bosco, Raffaella ^a   Ingrao, Sabrina ^c   Zavan, Barbara ^d   Zauli, Giorgio ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INFILTRATION; CANCER SURVIVAL; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; SCID MOUSE; THERAPY EFFECT; TUMOR NECROSIS; TUMOR XENOGRAFT; ANIMAL; COCULTURE; CYTOLOGY; HEMATOPOIETIC STEM CELL; MESENCHYMAL STEM CELL; MOUSE MUTANT; NUDE MOUSE; PATHOLOGY; XENOGRAFT;

MUS;

ANIMALS; COCULTURE TECHNIQUES; HEMATOPOIETIC STEM CELLS; HUMANS; LYMPHOMA, NON-HODGKIN; MESENCHYMAL STEM CELLS; MICE; MICE, NUDE; MICE, SCID; TRANSPLANTATION, HETEROLOGOUS;

EID: 77955239592     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011140     Document Type: Article

References (39)

1. Clarke CA, Glaser SL (2002) Changing incidence of non-Hodgkin lymphomas in the United States. Cancer 94: 2015-2023.
2. Armitage JO, Weisenburger DD (1998) New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes: Non-Hodgkin's Lymphoma classification project. J Clin Oncol 16: 2780-2795.
3. Taub R, Kirsch I, Morton C, Lenoir G, Swan D, et al. (1982) Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A 79: 7837-7841.
4. Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337.
5. Kaya NE, Shanafelta TD, Stregea AK, Leea YK, Bonea ND, et al. (2007) Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch." Leuk Res 31: 899-906.
6. Edelmann J, Klein-Hitpass L, Carpinteiro A, Führer A, Sellmann L, et al. (2008) Bone marrow fibroblasts induce expression of PI3K/NF-kB pathway genes and a pro-angiogenic phenotype in CLL cells. Leuk Res 32: 1565-1572.
7. Ning H, Yang F, Jiang M, Hu L, Feng K, et al. (2008) The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 22: 593-599.
8. Iwamoto S, Mihara K, Downing JR, Pui CH, Campana D (2007) Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 117: 1049-1057.
9. Guest I, Ilic Z, Ma J, Grant D, Glinsky G, et al. (2009) Direct and indirect contribution of bone marrow derived cells to cancer. Int J Cancer [Epub ahead of prin].
10. Hamada H, Kobune M, Nakamura K, Kawano Y, Kato K, et al. (2005) Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci 96: 149-156.
11. Aggarwal S, Pittenger MF (2004) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105: 1815-1822.
12. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, et al. (2003) Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102: 3837-3844.
13. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, et al. (2004) Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96: 1593-1603.
14. Kidd S, Spaeth E, Klopp A, Andreeff M, Hall B, et al. (2008) The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy 10: 657-667.
15. Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D, et al. (2007) Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 21: 304-310.
16. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, et al. (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449: 557-563.
17. Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, et al. (2008) Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res 68: 4331-4339.
18. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, et al. (2009) Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 4: e4992.
19. Au P, Tam J, Fukumura D, Jain RK (2008) Bone marrow derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood 111: 4551-4558.
20. Chen L, Tredget EE, Wu PYG, Wu Y (2008) Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PloS One 3: e1886.
21. Sato T, Sakai T, Noguchi Y, Takita M, Hirakawa S, et al. (2004) Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol 92: 47-56.
22. Zhu W, Xu W, Jiang R, Qian H, Chen M, et al. (2006) Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 80: 267-274.
23. De Wever O, Demetter P, Mareel M, Bracke M (2008) Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 123: 2229-2238.
24. Amé-Thomas P, Maby-El Hajjami H, Monvoisin C, Jean R, Monnier D, et al. (2007) Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood 109: 693-702.
25. Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, et al. (2007) Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia 21: 1521-1531.
26. Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, et al. (2007) Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nature Med 13: 944-951.
27. Ruan J, Hyjek E, Kermani P (2006) Magnitude of stromal hemangiogenesis correlates with histologic subtype of Non-Hodgkin's lymphoma. Clin Cancer Res 12: 5622-5631.
28. Chan DA, Kawahara TLA, Sutphin PD, Chang HY, Chi JT, et al. (2009) Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 15: 527-538.
29. Choi YB, Nicholas J (2010) Induction of angiogenic chemokine CCL2 by human herpesvirus 8. Virology 397: 369-378.
30. Trouillon R, Kang DK, Park H, Chang SI, O'Hare D (2010) Angiogenin induces nitric oxide synthesis in endothelial cells through PI-3 and Akt kinases. Biochemistry 49: 3282-3288.
31. De Becker A, Van Hummelen P, Bakkus M, Vande Broek I, De Wever J, et al. (2007) Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3. Haematologica 92: 440-449.
32. Zhu Y, Sun Z, Han Q, Liao L, Wang J, et al. (2009) Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia 23: 925-933.
33. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, et al. (2006) Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 203: 1235-1247.
34. Otsu K, Das S, Houser SD, Quadri SK, Bhattacharya S, et al. (2009) Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood 113: 4197-4205.
35. Lazennec G, Jorgensen C (2008) Concise Review: Adult multipotent stromal cells and cancer: risk or benefit? Stem Cells 26: 1387-1394.
36. Marini FC (2009) The complex love-hate relationship between mesenchymal stromal cells and tumors. Cytotherapy 11: 375-376.
37. Secchiero P, Corallini F, di Iasio MG, Gonelli A, Barbarotto E, et al. (2005) TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release. Blood 105: 3413-3419.
38. Secchiero P, Zerbinati C, di Iasio MG, Melloni E, Tiribelli M, et al. (2007) Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 8: 395-403.
39. Secchiero P, Zerbinati C, Rimondi E, Corallini F, Milani D, et al. (2004) TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61: 1965-1974.